NobleGen | GenomeWeb

NobleGen

The research team behind the Optipore sequencing strategy adopted by NobleGen Biosciences has published a new proof-of-principle study outlining the steps for fabricating nanopore arrays from solid-state material, as the company itself works to secure Series A financing.

This article has been updated from a previous version to clarify that Wave 80 is evaluating the SPE technology but has not licensed it.
By Ben Butkus

By Julia Karow
This article has been updated to include information about Roche/IBM and Genia.

Noblegen Biosciences has been awarded a $182,000 one-year phase I Small Business Innovation Research grant from the National Human Genome Research Institute to develop its "optipore" sequencing technology, the company disclosed this month.

New Products

Premium

Illumina has launched several products related to its MiSeq platform, including TruSeq Custom Amplicon Kits, Nextera DNA sample prep kits, and its BaseSpace Cloud Environment for storage and analysis.

The company has automated its DNA conversion process and will shortly install a second-generation prototype nanopore reader.

Paired Ends

Premium

Wolfgang Oster, Gavriel Meron, Chandra Venkatraman, George Church, Chad Nusbaum, Zhiping Weng, Jorge Leon

"The type of products that can be made with nanopores are very different and can give that revolutionary aspect [to genome sequencing] that PacBio or Ion Torrent can't," Oxford Nanopore's Spike Wilcocks told In Sequence.

Several grantees are affiliated with companies working on new commercial sequencing technologies, including GnuBio, Caerus Molecular Diagnostics, Oxford Nanopore Technologies, Intelligent Bio-Systems, NobleGen Biosciences, and Halcyon Molecular.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.